ArrowMark Colorado Holdings’s Immunovant IMVT Stock Holding History

ArrowMark Colorado Holdings’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-70,000	Closed	-$1.74M	–	308
2026 Q1	$1.74M	Hold	70,000	–	–	0.05%	227
2025 Q4	$1.78M	Hold	70,000	–	–	0.04%	249
2025 Q3	$1.13M	Hold	70,000	–	–	0.02%	250
2025 Q2	$1.12M	Hold	70,000	–	–	0.02%	252
2025 Q1	$1.2M	Hold	70,000	–	–	0.02%	243
2024 Q4	$1.73M	Hold	70,000	–	–	0.02%	240
2024 Q3	$2M	Hold	70,000	–	–	0.03%	230
2024 Q2	$1.85M	Hold	70,000	–	–	0.02%	245
2024 Q1	$2.26M	Sell	70,000 -3,550	-5%	-$130K	0.03%	240
2023 Q4	$3.1M	Hold	73,550	–	–	0.03%	222
2023 Q3	$2.82M	Buy	+73,550	New	+$1.66M	0.03%	217

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ArrowMark Colorado Holdings's IMVT Position: Q2 2026 in Review

ArrowMark Colorado Holdings sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 70,000 shares — an estimated $1.74M sold.

ArrowMark Colorado Holdings first reported a position in IMVT in Q3 2023 and held it in 11 quarters. The position peaked at $3.1M in Q4 2023. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

ArrowMark Colorado Holdings reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
ArrowMark Colorado Holdings sold 70,000 Immunovant shares in Q2 2026, an estimated $1.74M.
ArrowMark Colorado Holdings first reported a position in Immunovant in Q3 2023 and held it in 11 quarters.
ArrowMark Colorado Holdings's Immunovant position peaked at $3.1M in Q4 2023.
227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.